NCI Urges full Disclosure of Cigarette Contents

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md-The National Cancer Institute is urging the Federal Trade Commission (FTC) to replace its current cigarette testing protocol with one that provides the full range of tar, nicotine and carbon monoxide yields in individual cigarette brands.

BETHESDA, Md—The National Cancer Institute is urging the Federal Trade Commission (FTC) to replace its current cigarette testing protocol with one that provides the full range of tar, nicotine and carbon monoxide yields in individual cigarette brands.

The NCI's newest monograph in its series on Smoking and Tobacco Control contains the findings and recommendations of an expert committee that addressed the need for changes in the FTC's cigarette-testing method. The committee also recommended the following:

A public education campaign must accompany the new testing approach to make smokers aware that an individual's exposure depends on how a cigarette is smoked and that the benefits of switching to lower-yield cigarettes are small compared to quitting.

  • A simple, graphic representation of tar, nicotine, and carbon monoxide levels should appear on each pack sold and in all advertisements.
  • Other constituents in cigarettes should be listed on each pack and in all advertising, with each constituent classified by its toxic effects.
  • Terms such as "light" and "ultra light" represent health claims and should be regulated by the federal government.
  • Cigarette testing information should be available to the public, since it is useless unless smokers have access to it.
  • Questions about the purpose, methodology, and utility of the FTC's testing protocol are complex medical and scientific issues, and require the on-going involvement of federal health agencies.

Single copies of the monograph, "The FTC Cigarette Test Method for Determining Tar, Nicotine, and Carbon Monoxide Yields of US Cigarettes—Report of the NCI Expert Committee," are available from NCI at 1-800-422-6237.

Recent Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
4 experts in this video
4 experts in this video
Related Content